GI Dynamics has announced the commercial launch of the EndoBarrier gastrointestinal liner, a non-surgical device designed for the treatment of type 2 diabetes and obesity, in the Netherlands.

EndoBarrier is a thin, flexible, tube-shaped liner proven to lower blood-glucose levels and promote weight loss in diabetic and obese patients by creating a barrier between food and the wall of the intestine.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Clinical trials conducted in the Netherlands that involved around 100 patients demonstrated the efficacy of EndoBarrier in glycaemic control and weight loss.

Ignace Janssen, clinical study investigator and bariatric surgeon at Vitalys Obesitas Centrum at Rijnstate Hospital in Arnhem, said that the clinical trials with EndoBarrier helped them to develop an optimal treatment programme that will help ensure successful outcomes for the patients.

Vitalys Clinics director Martin Kirch said they hope the EndoBarrier can help obese diabetic patients in the lower BMI range, and offers an approach to better manage type 2 diabetes and related comorbidities.

See Also:

In a previous diabetes trial, type II diabetes patients treated with the EndoBarrier for 12 months achieved a mean 2.3% decrease in HbA1c levels, decreased glucose levels from an average of 175.6 at baseline to 137.8mg/dl and 39% excess weight loss.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier studies also revealed that the EndoBarrier affects certain gastrointestinal hormones involved in insulin sensitivity, glucose metabolism and satiety, and these changes enable rapid and sustained improvement of type 2 diabetes.

The EndoBarrier is commercially available in Chile, Germany, the UK, the Netherlands and Austria, and will soon be available in Australia.